Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Blood (2022) 140 (Supplement 1): 10434–10436.

https://doi.org/10.1182/blood-2022-169736

Published: 2022

Journal Articles

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Blood (2022) 140 (Supplement 1): 10514–10516.

https://doi.org/10.1182/blood-2022-162853

Published: 2022

Journal Articles

Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Depei Wu, Gwendolyn Van Gorkom, Marie Thérèse Rubio, Tobias Gedde-Dahl, Anne Huynh, Francesco Lanza, Norbert Claude Gorin, Sr., Mohamad Mohty, Silvia Maria Trisolini, Arnaud Pigneux

Blood (2021) 138 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2021-145031

Published: 2021

Journal Articles

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Blood (2021) 138 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2021-147001

Published: 2021

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Raffaele Palmieri, MD, Alfonso Piciocchi, Valentina Arena, MS, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Maria Irno Consalvo, Consuelo Conti, Cristina Attrotto, Daniela Fraboni, Maria Teresa Voso, MD, William Arcese, MD PhD, Adriano Venditti, MD, Francesco Buccisano, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139557

Published: 2020

Journal Articles

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Mohamed Amine Bekadja, Ariane Boumendil, Sr., PhD, Didier Blaise, MD, Patrice Chevalier, MD PhD, Karl S Peggs, MD PhD, Gilles Salles, MD PhD, Sebastian Giebel, Sr., Jürgen Finke, Sr., MD PhD, William Arcese, MD PhD, Noel Milpied, Hervé Finel, Sr., MD PhD, Norbert Claude Gorin, Sr., MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-133900

Published: 2020

Journal Articles

Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Joshua A Fein, MD, Roni Shouval, MD PhD, Myriam Labopin, MD, Fabio Ciceri, MD, Emanuele Angelucci, MD, Didier Blaise, MD, Johanna Tischer, William Arcese, MD PhD, Yener Koc, MD, Benedetto Bruno, MD, Jose L. Diez-Martin, MD PhD, Stella Santarone, MD, Simona Sica, MD PhD, Jurjen Versluis, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139519

Published: 2020

Journal Articles

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139773

Published: 2020

Journal Articles

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Giovanni Del Poeta, MD, Annalisa Biagi, MD, Annalisa Chiarenza, MD PhD, Luca Laurenti, MD, Federico Pozzo, MSc, Idanna Innocenti, MD PhD, Riccardo Bomben, PhD, Maria Ilaria Del Principe, Enrico Santinelli, MD, Francesca Maria Rossi, PhD, Paolo de Fabritiis, MD, Maria Cantonetti, Antonella Zucchetto, William Arcese, Valter Gattei, MD

Blood (2019) 134 (Supplement_1): 1744.

https://doi.org/10.1182/blood-2019-122481

Published: 2019

Journal Articles

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Raffaele Palmieri, MD, Giovangiacinto Paterno, Eleonora De Bellis, Elisa Buzzatti, Valentina Rossi, Ambra Di Veroli, MD, Fabiana Esposito, Lisa Mercante, Carmelo Gurnari, MD, Paola Casciani, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, MD, William Arcese, Adriano Venditti, Francesco Buccisano, MD

Blood (2019) 134 (Supplement_1): 2150.

https://doi.org/10.1182/blood-2019-127873

Published: 2019

Journal Articles

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Carmelo Gurnari, MD, Francesca Di Giuliano, Mariadomenica Divona, Alfonso Piciocchi, Laura Cicconi, Adriano Venditti, Maria Ilaria Del Principe, William Arcese, Francesco Lo-Coco, Francesco Garaci, MD, Maria Teresa Voso, MD

Blood (2019) 134 (Supplement_1): 5170.

https://doi.org/10.1182/blood-2019-125058

Published: 2019

Journal Articles

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Blood (2019) 134 (Supplement_1): 5083.

https://doi.org/10.1182/blood-2019-129184

Published: 2019

Journal Articles

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD, Raffaele Palmieri, MD, Maria Irno Consalvo, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Valentina Arena, Stefano Soddu, Ambra Di Veroli, MD, Giovangiacinto Paterno, Eleonora De Bellis, Daniela Fraboni, Consuelo Conti, Maria Teresa Voso, MD, William Arcese, Adriano Venditti

Blood (2019) 134 (Supplement_1): 2688.

https://doi.org/10.1182/blood-2019-128025

Published: 2019

Journal Articles

Mutational Profile of Leukemic Stem Cells in FLT3 -ITD Mutated AML

Blood (2019) 134 (Supplement_1): 1458.

https://doi.org/10.1182/blood-2019-126040

Published: 2019

Journal Articles

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Blood (2019) 134 (12): 935–945.

https://doi.org/10.1182/blood.2018886960

Published: 2019

Includes: Supplemental data

Journal Articles

Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, MD PhD, Myriam Labopin, MD, Giorgia Battipaglia, MD, Azedine Djabali, Edouard Forcade, MD, William Arcese, Gérard Socié, MDPhD, Didier Blaise, Jakob R. Passweg, MDMS, Jan J Cornelissen, MD PhD, Patrice Chevallier, MD, Johan Maertens, MD, Nicolaas Schaap, MD PhD, Khowla Hashaishi, MD, Jean Elcheikh, MD, Florent Malard, MDPhD, Jordi Esteve, MD PhD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2018) 132 (Supplement 1): 708.

https://doi.org/10.1182/blood-2018-99-114044

Published: 2018

Journal Articles

Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Blood (2018) 132 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2018-99-113074

Published: 2018

Journal Articles

The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Giovanni Del Poeta, MD, Massimiliano Postorino, MD, Federico Pozzo, PhD, Maria Ilaria Del Principe, MD, Enrico Santinelli, MD, Riccardo Bomben, PhD, Annalisa Biagi, MD, Francesco Buccisano, MD, Francesca Maria Rossi, PhD, Adriano Venditti, MD, Paolo de Fabritiis, MD, Maria Cantonetti, MD, Sergio Amadori, MD, Valter Gattei, MD, William Arcese

Blood (2018) 132 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2018-99-113060

Published: 2018

NARROW

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Mutational Profile of Leukemic Stem Cells in FLT3 -ITD Mutated AML

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party

Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only